Neuronetics, Inc. (NASDAQ:STIM) Short Interest Down 37.3% in November

Neuronetics, Inc. (NASDAQ:STIM) was the recipient of a significant decline in short interest in November. As of November 30th, there was short interest totalling 607,300 shares, a decline of 37.3% from the November 15th total of 969,100 shares. Based on an average daily volume of 452,500 shares, the days-to-cover ratio is presently 1.3 days.

Institutional Trading of Neuronetics

A number of institutional investors have recently added to or reduced their stakes in the business. HighTower Advisors LLC increased its stake in shares of Neuronetics by 55.5% during the 3rd quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock worth $187,000 after purchasing an additional 87,816 shares during the last quarter. Landscape Capital Management L.L.C. bought a new stake in Neuronetics in the third quarter worth $53,000. GSA Capital Partners LLP increased its position in Neuronetics by 64.5% during the third quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after buying an additional 30,837 shares during the last quarter. Gabelli Funds LLC raised its holdings in Neuronetics by 88.2% during the second quarter. Gabelli Funds LLC now owns 48,000 shares of the company’s stock valued at $86,000 after buying an additional 22,500 shares in the last quarter. Finally, First Eagle Investment Management LLC raised its holdings in Neuronetics by 33.4% during the second quarter. First Eagle Investment Management LLC now owns 1,039,009 shares of the company’s stock valued at $1,870,000 after buying an additional 260,000 shares in the last quarter. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Neuronetics Stock Down 3.4 %

Shares of Neuronetics stock traded down $0.04 during trading on Friday, hitting $1.12. 177,264 shares of the stock traded hands, compared to its average volume of 294,209. The company has a fifty day moving average price of $0.98 and a two-hundred day moving average price of $1.28. Neuronetics has a twelve month low of $0.52 and a twelve month high of $5.07. The stock has a market cap of $33.99 million, a P/E ratio of -0.91 and a beta of 2.25. The company has a debt-to-equity ratio of 4.90, a quick ratio of 2.87 and a current ratio of 3.16.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.